SitemapImprintDatenschutzerklärungdeutschenglish
MHH Logo

CABP study

COMBACTE - CABP Pilot study

COMBACTE (Combatting Bacterial Resistance in Europe)

 

 

Antimicrobial resistance (AMR) is a growing problem worldwide, and with few new drugs making it to the market, there is an urgent need for new medicines to treat resistant infections. Enter the IMI-funded COMBACTE project, which aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing efficient clinical trials for novel antibiotics. COMBACTE forms part of the New Drugs for Bad Bugs (ND4BB) initiative, IMI’s wider programme to tackle AMR.

 

Community-Acquired Bacterial Pneumonia (CABP) patient and COPD patients were recruited at two clinical sites.

 

 

 

patients:

  • 30 patients CABP (12/2015)
  • 15 patients COPD (12/2015)
  • controls

 

biomaterials:

  • EDTA blood
  • plasma
  • PAXgene
  • swabs
  • stool
  • sputum
  • urine

 

Consent:

  • specific consent